PMID- 37485542
OWN - NLM
STAT- MEDLINE
DCOM- 20230918
LR  - 20230918
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 111
IP  - 4
DP  - 2023 Oct
TI  - Efficacy of isatuximab in combination with steroids for the treatment of 
      relapsed/refractory multiple myeloma patients exhibiting only biochemical 
      progression-A single center retrospective study.
PG  - 628-635
LID - 10.1111/ejh.14057 [doi]
AB  - OBJECTIVES: Isatuximab is approved for treatment of relapsed/refractory multiple 
      myeloma (RRMM) with dexamethasone and carfilzomib or pomalidomide. Patients 
      receiving these three-drug regimens have exhibited more Grade >/= 3 adverse events 
      (AEs) compared to the two-drug class combination of isatuximab and steroids 
      alone. Thus, this single-center retrospective study investigated the efficacy of 
      isatuximab with dexamethasone and methylprednisolone (ISAdm) for RRMM patients 
      showing only biochemical progression (BP) of their disease. METHODS: Twenty-four 
      RRMM patients exhibiting only BP were administered isatuximab at 10 mg/kg with 
      dexamethasone once weekly for cycle 1 of a 28-day cycle, followed by every other 
      week for each cycle thereafter. Starting in cycle 2, oral methylprednisolone was 
      added every other day stopping 48 h before and starting 48 h after each 
      dexamethasone infusion. RESULTS: Overall response rate and clinical benefit rate 
      were 63% and 79%, respectively. Progression free survival was 12.9 months. There 
      were only 5 AEs of Grade >/= 3 which included lymphocytopenia (13%), leukopenia 
      (4%), and neutropenia (4%). No Grade >/= 3 AE related to respiratory infection, 
      anemia, or thrombocytopenia were reported. CONCLUSION: This study shows that the 
      two-drug class combination of ISAdm is an effective and well tolerated treatment 
      option for RRMM patients exhibiting only BP.
CI  - (c) 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Regidor, Bernard Sean
AU  - Regidor BS
AUID- ORCID: 0009-0001-7797-7026
AD  - Berenson Cancer Center, West Hollywood, California, USA.
FAU - Jew, Scott
AU  - Jew S
AUID- ORCID: 0009-0005-3450-7699
AD  - Berenson Cancer Center, West Hollywood, California, USA.
AD  - Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA.
FAU - Goldwater, Marissa-Skye
AU  - Goldwater MS
AUID- ORCID: 0009-0003-0103-5555
AD  - Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA.
FAU - Beatty, Bethany Marie
AU  - Beatty BM
AUID- ORCID: 0009-0004-4754-6446
AD  - Berenson Cancer Center, West Hollywood, California, USA.
FAU - Bujarski, Sean
AU  - Bujarski S
AUID- ORCID: 0009-0006-7994-7660
AD  - Berenson Cancer Center, West Hollywood, California, USA.
AD  - Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA.
FAU - ElSayed, Adam
AU  - ElSayed A
AUID- ORCID: 0000-0003-1213-2652
AD  - Berenson Cancer Center, West Hollywood, California, USA.
AD  - Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA.
FAU - Danis, Ryan
AU  - Danis R
AUID- ORCID: 0000-0002-8792-5510
AD  - Berenson Cancer Center, West Hollywood, California, USA.
FAU - Kim, Susanna
AU  - Kim S
AUID- ORCID: 0009-0009-3066-2447
AD  - Oncotherapeutics, West Hollywood, California, USA.
FAU - Swift, Regina
AU  - Swift R
AUID- ORCID: 0000-0002-0367-5965
AD  - Berenson Cancer Center, West Hollywood, California, USA.
FAU - Schwartz, Gary
AU  - Schwartz G
AUID- ORCID: 0009-0004-4691-1018
AD  - Berenson Cancer Center, West Hollywood, California, USA.
FAU - Berenson, James R
AU  - Berenson JR
AUID- ORCID: 0000-0003-1587-6104
AD  - Berenson Cancer Center, West Hollywood, California, USA.
AD  - Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA.
AD  - Oncotherapeutics, West Hollywood, California, USA.
LA  - eng
GR  - Institute for Myeloma and Bone Cancer Research/
PT  - Journal Article
DEP - 20230724
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - R30772KCU0 (isatuximab)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 0 (Steroids)
SB  - IM
MH  - Humans
MH  - *Multiple Myeloma/diagnosis/drug therapy/etiology
MH  - Retrospective Studies
MH  - Dexamethasone
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Steroids/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
OTO - NOTNLM
OT  - anti-CD38
OT  - isatuximab
OT  - multiple myeloma
OT  - relapsed/refractory
EDAT- 2023/07/24 06:42
MHDA- 2023/09/18 12:44
CRDT- 2023/07/24 05:00
PHST- 2023/07/06 00:00 [revised]
PHST- 2023/03/07 00:00 [received]
PHST- 2023/07/10 00:00 [accepted]
PHST- 2023/09/18 12:44 [medline]
PHST- 2023/07/24 06:42 [pubmed]
PHST- 2023/07/24 05:00 [entrez]
AID - 10.1111/ejh.14057 [doi]
PST - ppublish
SO  - Eur J Haematol. 2023 Oct;111(4):628-635. doi: 10.1111/ejh.14057. Epub 2023 Jul 
      24.